AbCellera Biologics Inc. (ABCL) research: valuation against peers, fundamentals over time, risk and news coverage
ChartVs peersValuationValue mapQuartersScaleMarginsTrajectoryCash qualityPer shareReinvestmentBalance sheetStreetRiskSeasonalityOur coverage
ABCL
AbCellera Biologics Inc.USD
11.32
-2.16% today
Market cap
—
P/E trailing
—
P/E forward
—
EV/EBITDA
—
Op margin
—
Rev growth
—
Div yield
—
Beta
—
Price navigator — ABCL
No data in this window.
INDY NEWS coverage of ABCL1
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- MARKET REPORTNEUTRALAbCellera jumps 22% on positive trial data
The antibody discovery company's shares rose sharply after it reported favourable clinical trial results.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.